Suppr超能文献

使用脑电图描记术和心理测试法对新型抗焦虑药舒氯克隆进行药代动力学和药效学研究。

Pharmacokinetic and -dynamic studies with a new anxiolytic, suriclone, utilizing EEG mapping and psychometry.

作者信息

Saletu B, Grünberger J, Linzmayer L, Semlitsch H V, Anderer P, Chwatal K

机构信息

Department of Psychiatry, School of Medicine, University of Vienna, Austria.

出版信息

Br J Clin Pharmacol. 1994 Feb;37(2):145-56. doi: 10.1111/j.1365-2125.1994.tb04254.x.

Abstract
  1. In a double-blind, placebo-controlled, cross-over study, acute pharmacokinetic, neurophysiological and psychotropic effects of suriclone, a new cyclopyrrolone derivative, were investigated and compared with alprazolam. 2. Fifteen normal young volunteers received randomized oral single doses of placebo, 0.1, 0.2 and 0.4 mg suriclone as well as 1 mg alprazolam as reference compound. Investigations were carried out before and 1, 2, 4, 6 and 8 h after drug administration. 3. Pharmacokinetic investigations by radioimmunoassay showed a dose-dependent fast rise of plasma concentrations with a peak at 1 h and a rapid decline thereafter. Both the Cmax and the AUC values exhibited a linear relationship to dose. 4. EEG brain mapping demonstrated significant CNS effects of both compounds, characteristic for tranquillizers (increase of beta, decrease of alpha and increase of delta activity; attenuation of total power and acceleration of the centroid, i.e. centre of gravity frequency). When compared with alprazolam, suriclone exerted less sedative effects. 5. Time-efficacy calculations showed the pharmacodynamic peak effect of suriclone from the 2nd to the 4th hour, and of alprazolam in the 1st hour. Dose-efficacy calculations showed that the most pronounced CNS changes occurred after 1 mg alprazolam, followed by 0.4, 0.2 and 0.1 mg suriclone. 6. Psychometric investigations demonstrated no significant effects after the two lower doses of suriclone, while 0.4 mg and 1 mg alprazolam induced a decrement both in noopsychic and thymopsychic variables seen after higher doses of anxiolytic sedatives. Psychophysiology (critical flicker fusion, pupillometry, and skin conductance measures) pulse rate, systolic and diastolic blood pressure remained unchanged. 7. Psychophysiology (critical flicker fusion, pupillometry and skin conductance measures) showed differential dose-dependent effects. Pulse rate, systolic and diastolic blood pressure remained unchanged. Anxiolytic-characteristic side-effects (tiredness, drowsiness, etc.) occurred predominantly after the highest doses 0.4 mg suriclone and 1 mg alprazolam.
摘要
  1. 在一项双盲、安慰剂对照、交叉研究中,对一种新型环吡咯酮衍生物舒立克隆的急性药代动力学、神经生理学和精神药理学效应进行了研究,并与阿普唑仑进行了比较。2. 15名正常年轻志愿者随机口服单剂量安慰剂、0.1、0.2和0.4毫克舒立克隆以及1毫克阿普唑仑作为参比化合物。在给药前以及给药后1、2、4、6和8小时进行研究。3. 通过放射免疫分析法进行的药代动力学研究表明,血浆浓度呈剂量依赖性快速上升,1小时时达到峰值,此后迅速下降。Cmax和AUC值均与剂量呈线性关系。4. 脑电图脑图谱显示两种化合物均有显著的中枢神经系统效应,这是镇静剂的特征(β波增加、α波减少和δ波活动增加;总功率衰减和重心频率加快,即重心频率)。与阿普唑仑相比,舒立克隆的镇静作用较小。5. 时效计算表明,舒立克隆的药效学峰值效应出现在第2至4小时,阿普唑仑的药效学峰值效应出现在第1小时。量效计算表明,最明显的中枢神经系统变化发生在1毫克阿普唑仑之后,其次是0.4、0.2和0.1毫克舒立克隆。6. 心理测量研究表明,较低剂量的舒立克隆没有显著影响,而0.4毫克和1毫克阿普唑仑在较高剂量的抗焦虑镇静剂后,在无精神和情绪心理变量方面均导致下降。心理生理学(临界闪烁融合、瞳孔测量和皮肤电导测量)、脉搏率、收缩压和舒张压均保持不变。7. 心理生理学(临界闪烁融合、瞳孔测量和皮肤电导测量)显示出不同的剂量依赖性效应。脉搏率、收缩压和舒张压均保持不变。抗焦虑特征的副作用(疲劳、嗜睡等)主要出现在最高剂量的0.4毫克舒立克隆和1毫克阿普唑仑之后。
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a8e/1364591/7d47e190c242/brjclinpharm00024-0026-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验